{
    "id": 26146,
    "fullName": "HDAC2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "HDAC2 over exp indicates an over expression of the Hdac2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3066,
        "geneSymbol": "HDAC2",
        "terms": [
            "HDAC2",
            "HD2",
            "KDAC2",
            "RPD3",
            "YAF1"
        ]
    },
    "variant": "over exp",
    "createDate": "03/09/2017",
    "updateDate": "01/21/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10240,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells over expressing HDAC1/2/3 demonstrated increased sensitivity to radiotherapy when treatment was combined with Valproic acid in culture, resulting in elevated apoptotic activity (PMID: 26980768).",
            "molecularProfile": {
                "id": 27328,
                "profileName": "HDAC1 over exp HDAC2 over exp HDAC3 over exp"
            },
            "therapy": {
                "id": 5430,
                "therapyName": "Radiotherapy + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8198,
                    "pubMedId": 26980768,
                    "title": "Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26980768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10241,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Valproic acid resulted in increased sensitivity to Lynparza (olaparib) treatment in melanoma cells over expressing HDAC1/2/3 in culture, demonstrating greater apoptotic activity (PMID: 26980768).",
            "molecularProfile": {
                "id": 27328,
                "profileName": "HDAC1 over exp HDAC2 over exp HDAC3 over exp"
            },
            "therapy": {
                "id": 4549,
                "therapyName": "Olaparib + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8198,
                    "pubMedId": 26980768,
                    "title": "Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26980768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10239,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells over expressing HDAC1/2/3 demonstrated increased sensitivity to Fotemustine when treatment was combined with Valproic acid in culture, resulting in elevated apoptotic activity (PMID: 26980768).",
            "molecularProfile": {
                "id": 27328,
                "profileName": "HDAC1 over exp HDAC2 over exp HDAC3 over exp"
            },
            "therapy": {
                "id": 5429,
                "therapyName": "Fotemustine + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8198,
                    "pubMedId": 26980768,
                    "title": "Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26980768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10238,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Valproic acid and Temodar (temozolomide) induced greater apoptotic activity in melanoma cells over expressing HDAC1/2/3 in culture compared to either agent alone, and suppressed tumor growth and reduced RAD51 and FANCD2 protein expression in melanoma cell line xenograft models (PMID: 26980768).",
            "molecularProfile": {
                "id": 27328,
                "profileName": "HDAC1 over exp HDAC2 over exp HDAC3 over exp"
            },
            "therapy": {
                "id": 5427,
                "therapyName": "Temozolomide + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8198,
                    "pubMedId": 26980768,
                    "title": "Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26980768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27326,
            "profileName": "HDAC2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27328,
            "profileName": "HDAC1 over exp HDAC2 over exp HDAC3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}